{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:34:47Z","timestamp":1793925287253,"version":"4.8.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Over the last years, the metabolic role of PRL has emerged. PRL excess is known to promote weight gain, obesity, metabolic syndrome, and impairment in gluco-insulinemic and lipid profiles, likely due to the suppression of physiologic dopaminergic tone. Prolactin receptors and dopamine receptors type 2 have been demonstrated to be expressed on both human pancreatic \u03b2- cell and adipocytes, supporting a key role of prolactin and dopamine in peripheral metabolic regulation. Medical treatment with the dopamine agonists bromocriptine and cabergoline has been demonstrated to decrease the prevalence of metabolic syndrome and obesity, and significantly improve gluco-insulinemic and lipid profiles. In hyperprolactinemic men with concomitant hypogonadism, correction of hyperprolactinaemia and testosterone replacement has been proven to restore metabolic impairment. In turn, low prolactin levels have also been demonstrated to exert a detrimental effect on weight gain, glucose and lipid metabolism, thus leading to an increased prevalence of metabolic syndrome. Therefore, PRL values ranging from 25 to 100 mg\/L, in absence of other recognizable pathological causes, have been proposed to represent a physiological response to the request for an increase in metabolic activity, and nowadays classify the so-called HomeoFIT- PRL as a promoter of metabolic homeostasis. The current review focuses mainly on the effects of hyperprolactinemia and its control by medical treatment with DAs on the modulation of food intake, body weight, gluco-insulinemic and lipid profile. Furthermore, it provides the latest knowledge about the metabolic impact of hypoprolactinemia.<\/jats:p>","DOI":"10.3389\/fendo.2022.1015520","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T09:56:02Z","timestamp":1664272562000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":114,"title":["Metabolic effects of prolactin"],"prefix":"10.3389","volume":"13","author":[{"given":"Rosa","family":"Pirchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Graziadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata S.","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","article-title":"The effects of hyperprolactinemia and its control on metabolic diseases","volume":"13","author":"Auriemma","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.02.005","article-title":"Focus on prolactin as a metabolic hormone","volume":"17","author":"Ben-Jonathan","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Endocrine society. diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8451","article-title":"Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones","volume":"33","author":"Baptista","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","article-title":"Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine","volume":"147","author":"Doknic","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00671.x","article-title":"Adipocyte prolactin: regulation of release and putative functions","volume":"9","author":"Brandebourg","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2826.2003.01092.x","article-title":"Changes in agouti-related peptide during the ring dove breeding cycle in relation to prolactin and parental hyperphagia","volume":"15","author":"Strader","year":"2003","journal-title":"J Neuroendocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000054522","article-title":"Dopaminergic agonists normalize elevated hypothalamic neuropeptide y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob\/ob mice","volume":"71","author":"Bina","year":"2000","journal-title":"Neuroendocrinology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.01.004","article-title":"Time for a new perspective on prolactin in metabolism","volume":"31","author":"Macotela","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979040","article-title":"Adaptation of islets of langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones","volume":"29","author":"Sorenson","year":"1997","journal-title":"Horm Metab Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-07-0043","article-title":"Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy","volume":"193","author":"Weinhaus","year":"2007","journal-title":"J Endocrinol"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(17)36838-2","article-title":"Tissue distribution and regulation of rat prolactin receptor gene expression. quantitative analysis by polymerase chain reaction","volume":"269","author":"Nagano","year":"1994","journal-title":"J Biol Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/endo.133.3.8365359","article-title":"Effects of sex and pregnancy hormones on growth hormone and prolactin receptor gene expression in insulin-producing cells","volume":"133","author":"M\u00f8ldrup","year":"1993","journal-title":"Endocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0201","article-title":"Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans","volume":"145","author":"Brelje","year":"2004","journal-title":"Endocrinology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.20.15399","article-title":"Targeted expression of placental lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation, and hypoglycemia","volume":"275","author":"Vasavada","year":"2000","journal-title":"J Biol Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF00745135","article-title":"Prolactin: a diabetogenic hormone","volume":"13","author":"Landgraf","year":"1977","journal-title":"Diabetologia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb03397.x","article-title":"Hyperinsulinaemia in hyperprolactinemic women","volume":"13","author":"Johnston","year":"1980","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00273860","article-title":"Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo","volume":"28","author":"Schernthaner","year":"1985","journal-title":"Diabetologia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-9931-0","article-title":"Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia","volume":"44","author":"Atmaca","year":"2013","journal-title":"Endocrine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(98)70540-X","article-title":"Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy","volume":"178","author":"Highman","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.2.3731","article-title":"Leptin in human reproduction: serum leptin levels in pregnant and lactating women","volume":"82","author":"Butte","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-008-0140-4","article-title":"The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia","volume":"12","author":"Balci","year":"2009","journal-title":"Pituitary"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1018","article-title":"Induction of central leptin resistance in hyperphagic pseudopregnant rats by chronic prolactin infusion","volume":"149","author":"Augustine","year":"2008","journal-title":"Endocrinology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-8993(00)02344-1","article-title":"Neuroanatomical specificity of prolactininduced hyperphagia in virgin female rats","volume":"868","author":"Sauv\u00e9","year":"2000","journal-title":"Brain Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032184","article-title":"Prolactin release is enhanced in proportion to excess visceral fat in obese women","volume":"89","author":"Kok","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-6823-10-10","article-title":"Prolactinomas, cushing\u2019s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas","volume":"17","author":"Biller","year":"2010","journal-title":"BMC Endocr Disord"},{"key":"B30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000499470","article-title":"Dopamine agonists: From the 1970s to today","volume":"109","author":"Auriemma","year":"2019","journal-title":"Neuroendocrinology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(91)90057-4","article-title":"Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulicoronan resistance, and impaired glucose tolerance in the Syrian hamster, mesocricetus auratus","volume":"40","author":"Cincotta","year":"1991","journal-title":"Metabolism"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1993.264.2.E285","article-title":"Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters","volume":"264","author":"Cincotta","year":"1993","journal-title":"Am J Physiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.6.667","article-title":"Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects","volume":"19","author":"Cincotta","year":"1996","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1697","article-title":"Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women","volume":"20","author":"Kamath","year":"1997","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.6.667","article-title":"Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects","volume":"19","author":"Cincotta","year":"1996","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2005.18.9.921","article-title":"Reversible weight gain and prolactin levels\u2013long-term follow-up in childhood","volume":"18","author":"Galluzzi","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01304.x","article-title":"Bromocriptine: old drug, new formulation and new indication","volume":"12","author":"Holt","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004818","article-title":"Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial","volume":"95","author":"Bahar","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-015-0094-4","article-title":"Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline","volume":"7","author":"Pala","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"B42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","article-title":"Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy","volume":"14","author":"Berinder","year":"2011","journal-title":"Pituitary"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345636","article-title":"Body fat in men with prolactinoma","volume":"31","author":"Naliato","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02973.x","article-title":"Body fat in nonobese women with prolactinoma treated with dopamine agonists","volume":"67","author":"Naliato","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists","volume":"19","author":"dos Santos Silva","year":"2011","journal-title":"Obes (Silver Spring)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.46","article-title":"Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia","volume":"11","author":"Korner","year":"2003","journal-title":"Obes Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12204","article-title":"Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels","volume":"79","author":"Ciresi","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000357810","article-title":"Effect of cabergoline on metabolism in prolactinomas","volume":"98","author":"Auriemma","year":"2013","journal-title":"Neuroendocrinology"},{"key":"B49","article-title":"Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas","volume":"131","author":"Bhansali","year":"2010","journal-title":"Indian J Med Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02461.x","article-title":"The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinemic males","volume":"64","author":"De Rosa","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000371851","article-title":"Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas","volume":"101","author":"Auriemma","year":"2015","journal-title":"Neuroendocrinology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.01206.x","article-title":"Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction","volume":"6","author":"Corona","year":"2009","journal-title":"J Sex Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12327","article-title":"Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male aging study (EMAS)","volume":"11","author":"Corona","year":"2014","journal-title":"J Sex Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr Rev"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201902357R","article-title":"Chronic high prolactin levels impact on gene expression at discrete hypothalamic nuclei involved in food intake","volume":"34","author":"Lopez-Vicchi","year":"2020","journal-title":"FASEB J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12902-021-00733-6","article-title":"Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study","volume":"21","author":"Posawetz","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/jcu.23030","article-title":"Is there an increased cardiovascular risk in patients with prolactinoma? a challenging question","volume":"49","author":"Yazici","year":"2021","journal-title":"J Clin Ultrasound"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1055\/a-1020-3992","article-title":"Markers of metabolic syndrome in patients with pituitary adenoma: A case series of 303 patients","volume":"51","author":"Altunta\u015f","year":"2019","journal-title":"Horm Metab Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02469.x","article-title":"The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy","volume":"64","author":"Serri","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.jcte.2021.100258","article-title":"Impact of primary medical or surgical therapy on prolactinoma patients\u2019 BMI and metabolic profile over the long-term","volume":"24","author":"Andereggen","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769744","article-title":"Effects of pituitary surgery and high-dose cabergoline therapy on metabolic profile in patients with prolactinoma resistant to conventional cabergoline treatment","volume":"12","author":"Pirchio","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2464","article-title":"Associations between circulating reproductive hormones and SHBG and prevalent and incident metabolic syndrome in community-dwelling older men: the concord health and ageing in men project","volume":"99","author":"Hsu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0890","article-title":"Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male ageing study","volume":"168","author":"Camacho","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01123-2","article-title":"Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence","volume":"24","author":"Giovinazzo","year":"2021","journal-title":"Pituitary"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14146","article-title":"Obesity is common at diagnosis of childhood pituitary adenoma and may persist following successful treatment","volume":"92","author":"Sethi","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1472-6823-13-12","article-title":"Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes","volume":"13","author":"Balbach","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00327","article-title":"Glucose abnormalities associated to prolactin secreting pituitary adenomas","volume":"10","author":"Auriemma","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1210\/endo.133.5.8404674","article-title":"Effects of steroid and lactogenic hormones on islets of langerhans: a new hypothesis for the role of pregnancy steroids in the adaptation of islets to pregnancy","volume":"133","author":"Sorenson","year":"1993","journal-title":"Endocrinology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1210\/endo.132.2.8425500","article-title":"Effect of homologous placental lactogens, prolactins, and growth hormones on islet b-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy","volume":"132","author":"Brelje","year":"1993","journal-title":"Endocrinology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1640277","article-title":"Prolactin induction of insulin gene expression: the roles of glucose and glucose transporter-2","volume":"164","author":"Petryk","year":"2000","journal-title":"J Endocrinol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.7.8267","article-title":"Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5","volume":"142","author":"Fleenor","year":"2001","journal-title":"Endocrinology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3904\/kjim.1993.8.1.8","article-title":"Direct relationship between elevated free testosterone and insulin resistance in hyperprolactinemic women","volume":"8","author":"Kim","year":"1993","journal-title":"Korean J Intern Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1982.tb00731.x","article-title":"Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma","volume":"16","author":"Pelkonen","year":"1982","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb00541.x","article-title":"Peripheral glucose metabolism in human hyperprolactinaemia","volume":"43","author":"Foss","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505560200","article-title":"Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion","volume":"280","author":"Rub\u00ed","year":"2005","journal-title":"J Biol Chem"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/BF00745138","article-title":"Accumulation of dopamine in mouse pancreatic b-cells following injection of l-DOPA. localization to secretory granules and inhibition of insulin secretion","volume":"13","author":"Ericson","year":"1977","journal-title":"Diabetologia"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/BF00251017","article-title":"Effect of increased pancreatic islet norepinephrine, dopamine and serotonin concentration on insulin secretion in the golden hamster","volume":"18","author":"Zern","year":"1980","journal-title":"Diabetologia"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1159\/000114744","article-title":"Effects of long-term l-dopa therapy on carbohydrate metabolism in patients with parkinson\u2019s disease","volume":"14","author":"Rosati","year":"1976","journal-title":"Eur Neurol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789x.2000.00019.x","article-title":"Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999","volume":"1","author":"Ayyad","year":"2000","journal-title":"Obes Rev"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-13-0549","article-title":"Successful diet and exercise therapy as evaluated on self-assessment score significantly improves endothelial function in metabolic syndrome patients","volume":"77","author":"Matsuzawa","year":"2013","journal-title":"Circ J"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0001","article-title":"Short-term treatment with bromocriptine improves impaired circadian growth hormone secretion in obese premenopausal women","volume":"93","author":"Kok","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.18632\/aging.100484","article-title":"Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians\u2019 offspring","volume":"4","author":"Vitale","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00771","article-title":"Novel trajectories of bromocriptine antidiabetic action: Leptin-IL-6\/JAK2\/p-STAT3\/SOCS3, p-IR\/p-AKT\/GLUT4, PPAR-\u03b3\/Adiponectin, Nrf2\/PARP-1, and GLP-1","volume":"9","author":"Reda","year":"2018","journal-title":"Front Pharmacol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1893","article-title":"Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study","volume":"36","author":"Wang","year":"2013","journal-title":"Diabetes Care"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2018.07.007","article-title":"An investigation of the association between the level of prolactin in serum and type II diabetes","volume":"13","author":"Manshaei","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4733-9","article-title":"Circulating prolactin concentrations and risk of type 2 diabetes in US women","volume":"61","author":"Li","year":"2018","journal-title":"Diabetologia"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0043","article-title":"Maternal serum prolactin and prediction of postpartum \u03b2-cell function and risk of Prediabetes\/Diabetes","volume":"39","author":"Retnakaran","year":"2016","journal-title":"Diabetes Care"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03145-1","article-title":"Cardiometabolic profile of young women with hypoprolactinemia","author":"Krysiak","year":"2022","journal-title":"Endocrine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-12114-7_1","article-title":"Prolactin (PRL) in adipose tissue: regulation and functions","volume":"846","author":"Ben-Jonathan","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2015.01.024","article-title":"Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia","volume":"84","author":"Medic-Stojanoska","year":"2015","journal-title":"Med Hypotheses"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1000184","article-title":"Interrelationship between TSH- and prolactin secretion in patients with prolactinoma and autoimmune thyroiditis","volume":"100","author":"Pelkonen","year":"1982","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/BF01721038","article-title":"Chronic hyperprolactinemia and plasma lipids in women","volume":"65","author":"Heshmati","year":"1987","journal-title":"Klin Wochenschr"},{"key":"B94","article-title":"Decreased apolipoprotein levels in women with hyperprolactinemia related to increased estradiol level: effect of hepatic lesion","volume":"19","author":"Oravec","year":"1985","journal-title":"Endocrinol Exp"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1210\/endo.137.12.8940406","article-title":"Prolactin receptor expression during adipocyte differentiation of bone marrow stroma","volume":"137","author":"McAveney","year":"1996","journal-title":"Endocrinology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2826.1998.00275.x","article-title":"Prolactin receptor gene expression and foetal adipose tissue","volume":"10","author":"Symonds","year":"1998","journal-title":"J Neuroendocrinol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.11.7147","article-title":"Prolactin stimulates leptin secretion by rat white adipose tissue","volume":"140","author":"Gualillo","year":"1999","journal-title":"Endocrinology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1172","article-title":"Prolactin release by adipose explants, primary adipocytes, and LS14 adipocytes","volume":"93","author":"Hugo","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025537","article-title":"Dopamine receptors in human adipocytes: expression and functions","volume":"6","author":"Borcherding","year":"2011","journal-title":"PloS One"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1825","article-title":"AlkaMeSy study group. visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-016-9882-2","article-title":"Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas","volume":"32","author":"Schwetz","year":"2017","journal-title":"Metab Brain Dis"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-4889(98)00092-5","article-title":"Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob\/ob mice","volume":"1405","author":"Liang","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"B103","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/MJT.0b013e318160c353","article-title":"Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects","volume":"15","author":"Contreras","year":"2008","journal-title":"Am J Ther"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.035","article-title":"Prolactin improves hepatic steatosis via CD36 pathway","volume":"68","author":"Zhang","year":"2018","journal-title":"J Hepatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2017.15","article-title":"Prolactin as a predictor of endothelial dysfunction and arterial stiffness progression in menopause","volume":"31","author":"Georgiopoulos","year":"2017","journal-title":"J Hum Hypertens"},{"key":"B106","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.maturitas.2021.06.014","article-title":"Hyperprolactinemia after menopause: Diagnosis and management","volume":"151","author":"Auriemma","year":"2021","journal-title":"Maturitas"},{"key":"B107","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12020-014-0308-9","article-title":"The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons","volume":"48","author":"Faje","year":"2015","journal-title":"Endocrine"},{"key":"B108","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11102-019-00998-0","article-title":"Prolactinomas and menopause: any changes in management","volume":"23","author":"Greenman","year":"2020","journal-title":"Pituitary"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345182","article-title":"Insulin sensitivity and hyperprolactinemia","volume":"26","author":"Tuzcu","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0183-1","article-title":"Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique","volume":"12","author":"Tuzcu","year":"2009","journal-title":"Pituitary"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12183","article-title":"Prolactin in obese children: a bridge between inflammation and metabolic-endocrine dysfunction","volume":"79","author":"Chirico","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03752.x","article-title":"Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma","volume":"73","author":"Erem","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B113","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/HYPERTENSIONAHA.109.132100","article-title":"Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors","volume":"54","author":"Georgiopoulos","year":"2009","journal-title":"Hypertension"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1015520\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T09:56:08Z","timestamp":1664272568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1015520\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":113,"alternative-id":["10.3389\/fendo.2022.1015520"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1015520","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"1015520"}}